Survival rates are lower for patients with high-risk melanoma with mutations

the ONA take:

Researchers from UNC Lineberger Comprehensive Cancer Center analyzed melanoma samples to determine if tumors with the BRAF or NRAS gene mutations indicated poorer prognosis for those patients.

This study was conducted before new treatments for melanoma were approved, including the first BRAF inhibitor approved in 2011. Therefore, the connection between the mutations and outcomes were determined without the influence of the new drugs.

In this study, 912 patients with melanoma were followed for 7 years. All the patients were enrolled through the GEM study, and their diagnoses were made in 2000.

Thirteen percent of patients had tumors with NRAS mutations, 30% had BRAF mutations, and 57% had neither mutation. The researchers found that 73% of patients with high-risk, NRAS-mutated tumors and 71% of patients with high-risk, BRAF-mutated tumors survived 5 years, compared with 82% of high-risk tumors with neither mutation.

Overall, no statistical difference was seen in 5-year survival for people with NRAS or BRAF mutations compared with those people who had no mutation.

However, 5-year survival was lower in people with high-risk tumors with mutations.

Survival rates are lower for patients with high-risk melanoma with mutations
No statistical difference was seen in 5-year survival for melanoma patients with NRAS or BRAF mutations.
Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in patients.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs